Brain Cancer | Specialty

The OncLive Brain Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of brain cancer, including glioma, glioblastoma multiforme, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

Dr. Sadai on Signs and Symptoms of High-Grade Meningiomas

April 4th 2023

Nader Sanai, MD, discusses symptoms associated with high-grade meningiomas, a rare brain tumor.

Dr. Brastianos on Recent Data in High-Grade Meningiomas

April 4th 2023

Priscilla K. Brastianos, MD, reviews recent findings in high-grade meningiomas, including data generated in her laboratory.

Improved Understanding of Genomics Drives Excitement in High-Grade Meningiomas

March 31st 2023

At present, there are no FDA-approved systemic therapies for patients with high-grade meningiomas. However, there has been an increase in research surrounding the disease over the past decade, which is improving the prospect a targeted agent may become for this population.

FDA Grants Orphan Drug Designation to FORE8394 for Primary Brain and CNS Malignancies

March 21st 2023

The FDA has granted an orphan drug designation to FORE8394 for the treatment of primary brain and central nervous system malignancies.

FDA Approves Dabrafenib Plus Trametinib for Pediatric Patients With BRAF V600E–Mutated Low-Grade Glioma

March 16th 2023

The FDA has approved dabrafenib with trametinib for the treatment of pediatric patients 1 year of age and older with low-grade glioma with a BRAF V600E mutation who require systemic therapy.

Vorasidenib Meets PFS End Point in IDH1/2-Mutant Low-Grade Glioma

March 14th 2023

Vorasidenib monotherapy elicited a statistically significant and clinically meaningful improvement in progression-free survival compared with placebo in patients with residual or recurrent IDH1/2-mutant low-grade glioma.

Will Immunotherapy Become a Standard of Care for Glioblastoma?

March 10th 2023

Given the current lack of positive phase 3 immunotherapy trials for glioblastoma, a misconception held by oncologists and neuro-oncologists is that immunotherapy has no place in this malignancy.

Temferon Lands FDA Orphan Drug Status for Glioblastoma Multiforme

March 2nd 2023

The FDA has granted an orphan drug designation to Temferon for use as a potential therapeutic option in patients with glioblastoma multiforme.

FDA Grants Orphan Drug Designation to BEA-17 for Glioblastoma

February 1st 2023

The FDA has granted an orphan drug designation to BEA-17 for the treatment of patients with glioblastoma.

Dr. Ahluwalia on the Evaluation of SurVaxM With Temozolomide in Newly Diagnosed Glioblastoma

January 10th 2023

Manmeet Singh Ahluwalia, MD, discusses the evaluation of SurVaxM in combination with oral temozolomide in patients with newly diagnosed glioblastoma.

FDA Grants Orphan Drug Designation to Azeliragon for Glioblastoma

January 10th 2023

The FDA has granted an orphan drug designation to azeliragon for the treatment of patients with glioblastoma.

Tovorafenib Elicits Responses in Recurrent or Progressive Pediatric Low-Grade Glioma

January 9th 2023

Tovorafenib monotherapy generated responses in patients with recurrent or progressive pediatric low-grade glioma.

FDA Grants Breakthrough Device Designation for Blood Test for Inaccessible Brain Tumors

January 4th 2023

The FDA has granted breakthrough device designation for the TriNetra™-Glio blood test to help in the diagnosis of brain tumors.

EMA Committee Advises Against Approval of Omburtamab for Neuroblastoma

January 3rd 2023

The European Committee for Medicinal Products for Human Use has announced that it does not support the marketing authorization of omburtamab for the treatment of patients with central nervous system/leptomeningeal metastasis from neuroblastoma.

A New Take on Preclinical Drug Trials for Glioblastoma Treatment

December 14th 2022

The Ivy Brain Tumor Center at Barrow Neurological Institute in Phoenix, Arizona, is attempting to change the way preclinical studies are developed and conducted to assess the efficacy of drugs for glioblastoma multiforme.

FDA Issues Complete Response Letter for Omburtamab BLA for Pediatric Metastatic Neuroblastoma

December 2nd 2022

The FDA has issued a complete response letter to the biologics license application seeking the approval of 131I-omburtamab for the treatment of pediatric patients with central nervous system/leptomeningeal metastases from neuroblastoma.

FDA Grants Orphan Drug Designation to AUM302 for Neuroblastoma

December 2nd 2022

The FDA has granted an orphan drug designation to AUM302 for the treatment of patients with neuroblastoma.

DCVax-L Improves Survival in Glioblastoma

November 18th 2022

Autologous tumor lysate-loaded dendritic cell vaccination used in combination with standard-of-care treatment extended overall survival for patients with newly diagnosed glioblastoma as well as those with recurrent disease.

ODAC Votes Against Omburtamab for Pediatric Metastatic Neuroblastoma

October 31st 2022

In a 16 to 0 vote, the FDA’s Oncologic Drugs Advisory Committee voted that sufficient evidence has not been provided to conclude that 131I-omburtamab improves overall survival for pediatric patients with central nervous system /leptomeningeal metastases from neuroblastoma.

FDA Raises Questions About BLA for Omburtamab in Pediatric Metastatic Neuroblastoma

October 27th 2022

The FDA has expressed concern about the efficacy of 131I-omburtamab prior to a meeting of the regulatory agency’s ODAC to examine data supporting the BLA seeking the agent’s approval for the treatment of pediatric patients with central nervous system/leptomeningeal metastases from neuroblastoma.